Avaliação da ação terapêutica adjuvante do extrato de Passiflora edulis na prevenção da doença renal diabética em modelo animal de diabetes tipo 1: identificação da proteína megalina como biomarcador precoce de lesão renal

Abstract

Diabetic Kidney Disease (DRD) is a common complication of Type 1 Diabetes Mellitus (DM1) that results in loss of protein, such as megalin, into the urinary space due to tubular changes. The management of DM1 is done with insulin therapy, however, glycemic control remains a challenge for many patients, and in this scenario, adjuvant therapies have been extensively studied. In view of this, the present study sought to evaluate the adjuvant therapeutic action of Passiflora edulis extract to insulin in the prevention of DRD, through the identification of megalin as a biomarker of renal injury. For this, 37 Wistar rats with DM1, induced by streptozotocin, were divided into four groups: control (CTL), diabetic (DB), insulin (INS) and insulin+P. edulis extract (INS+AFA), treated by 60 days. Biochemical, histological and molecular data were evaluated. Animals treated with INS+AFA showed positively significant results for glycemic control, reduction in the urinary albumin/creatinine ratio, maintenance of basal levels of Lrp2 expression, prevention of megalin loss from the renal tissue to the urinary space and preservation of the structure renal when compared to the DB and INS groups, respectively. Suggesting that the association of INS+AFA can control and prevent DRD.